



28 February 2019

**Surgical Innovations Group plc**  
(“Surgical Innovations”, the “Company”, or the “Group”)

### **Appointment of CEO and changes in senior management**

Surgical Innovations (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, announces the appointment of David Marsh as Chief Executive Officer (“CEO”) and provides details of changes to its management structure and responsibilities. All changes with the exception of the appointment of a new Operations Director are effective immediately.

David joined the Board of the Company as Group Commercial Director on the acquisition of Elemental Healthcare Limited (“Elemental”) in August 2017 reporting to Nigel Rogers, Executive Chairman. Prior to becoming a founding director of Elemental in 2006, he was European VP of Sales & Marketing at Gyrus International Limited.

David’s appointment as CEO of the Company gives rise to the following changes in Board and senior management responsibilities:

- Nigel Rogers, Executive Chairman will relinquish his executive responsibilities and become Non-Executive Chairman with immediate effect.
- Melanie Ross, CFO/COO will hand over her COO responsibilities to a newly appointed Operations Director of Surgical Innovations Limited with effect from 18 March 2019. This change will enable her to focus solely on her role as CFO with emphasis on all Group finance matters, investor relations and M&A activities.
- Adam Power, Group Business Development Director (Board position) will take sole responsibility for all commercial and business development activities of the group with immediate effect.
- Alex Hogg will join the senior management team of the Company on 18 March 2019 as Operations Director at Surgical Innovations Limited (a non plc Board position). He was previously Production Director at Xiros Limited, a medical device development company based in Leeds.

**Nigel Rogers, Executive Chairman commented:** *“These changes conclude the successful acquisition and integration of Elemental into the Group and will allow Surgical Innovations to be even more proactive in meeting the demands of its global healthcare customers and partners.*

*We look forward to an exciting future for the Group with the benefit of David’s leadership qualities and wide industry experience. Following these changes, we have a very strong executive team capable of capitalising on organic growth opportunities and delivering exciting additional prospects through collaborative partnerships and further M&A activity.”*

**For further information contact:**

**Surgical Innovations Group Plc**

Nigel Rogers, Executive Chairman

Melanie Ross, COO and CFO

[www.sigroupplc.com](http://www.sigroupplc.com)

Tel: +44 (0)113 230 7597

**Walbrook PR (Financial PR & Investor Relations)**

Paul McManus

Lianne Cawthorne

Tel: +44 (0)20 7933 8780 or

[si@walbrookpr.com](mailto:si@walbrookpr.com)

Mob: +44 (0)7980 541 893

Mob: +44 (0)7584 391 303

**N+1 Singer (Nominated Adviser and Broker)**

Richard Lindley

Rachel Hayes

+44 (0)20 7496 3000